SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Ikeda K, Saitoh S, Suzuki Y, et al. Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: a prospective observation of 2215 patients. J Hepatol. 1998; 28: 930938.
  • 2
    Kenny-Walsh E, for the Irish Hepatology Research Group. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. N Engl J Med. 1999; 340: 12281233.
  • 3
    Alberti A, Noventa F, Benvegnu L, Boccato S, Gatta A. Prevalence of liver disease in a population of asymptomatic persons with hepatitis C virus infection. Ann Intern Med. 2002; 17: 961964.
  • 4
    Aizawa Y, Shibamoto Y, Takagi I, et al. Analysis of factors affecting the appearance of hepatocellular carcinoma in patients with chronic hepatitis C. A long term follow-up study after histologic diagnosis. Cancer. 2000; 89: 5359.
  • 5
    Khan MH, Farrell GC, Byth K, et al. Which patients with hepatitis C develop liver complications? Hepatology. 2000; 31: 513520.
  • 6
    Shibata M, Morizane T, Uchida T, et al. Irregular regeneration of hepatocytes and risk of hepatocellular carcinoma in chronic hepatitis and cirrhosis with hepatitis-C-virus infection. Lancet. 1998; 351: 17731777.
  • 7
    Kasahara A, Hayashi N, Mochizuki K, et al. Clinical characteristics of patients with chronic hepatitis C showing biochemical remission, without hepatitis C eradication, as a result of interferon therapy. The Osaka Liver Disease Study Group. J Viral Hepatol. 2000; 7: 343351.
  • 8
    Okanoue T, Itoh Y, Minami M, et al. Interferon therapy lowers the rate of progression to hepatocellular carcinoma in chronic hepatitis C but not significantly in an advanced stage: a retrospective study in 1148 patients. J Hepatol. 1999; 30: 653659.
  • 9
    Kasahara A, Hayashi N, Mochizuki K, et al. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Osaka Liver Disease Study Group. Hepatology. 1998; 27: 13941402.
  • 10
    Okanoue T, Itoh Y, Kirishima T, et al. Transient biochemical response in interferon therapy decreases the development of hepatocellular carcinoma for five years and improves the long-term survival of chronic hepatitis C patients. Hepatol Res. 2002; 23: 6277.
  • 11
    Yoshida H, Shiratori Y, Moriyama M, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. Ann Intern Med. 1999; 131: 174181.
  • 12
    Imai Y, Kawata S, Tamura S, et al. Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Ann Intern Med. 1998; 129: 9499.
  • 13
    Ikeda K, Saitoh S, Arase Y, et al. Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis. Hepatology. 1999; 29: 11241130.
  • 14
    Tanaka H, Tsukuma H, Kasahara A, et al. Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: a retrospective cohort study of 738 patients. Int J Cancer. 2000; 87: 741749.
  • 15
    Hirashima N, Mizokami M, Orito E, et al. Development of hepatocellular carcinoma in a patient with chronic hepatitis C infection after a complete and sustained response to interferon-alpha. J Gastroenterol Hepatol. 1996; 11: 955958.
  • 16
    Inoue M, Ohhira M, Ohta T, et al. Hepatocellular carcinoma developed in a patient with chronic hepatitis C after the disappearance of hepatitis C virus due to interferon therapy. Hepatogastroenterology. 1999; 46: 25542560.
  • 17
    Miyano S, Togashi H, Shinzawa H, et al. Case report: occurrence of hepatocellular carcinoma 4.5 years after successful treatment with virus clearance for chronic hepatitis C. J Gastroenterol Hepatol. 1999; 14: 928930.
  • 18
    Tamori A, Kuroki T, Nishiguchi S, et al. Case of hepatocellular carcinoma in the caudate lobe detected after interferon caused disappearance of hepatitis C virus. Hepatogastroenterology. 1996; 43: 10791083.
  • 19
    Kim SR, Matsuoka T, Maekawa Y, et al. Development of multicentric hepatocellular carcinoma after completion of interferon therapy. J Gastroenterol. 2002; 37: 663668.
  • 20
    Okamura K, Yamazaki K, Ohmura T, et al. A resected case of hepatocellular carcinoma with sustained response to interferon for five years. Acta Hepatol Jpn. 2000; 41: 4347.
  • 21
    Yamada M, Ichikawa M, Matsubara A, Ishiguro Y, Yamada M, Yokoi S. Development of small hepatocellular carcinoma 80 month after clearance of hepatitis C virus with interferon therapy. Eur J Gastroenterol Hepatol. 2000; 12: 10291032.
  • 22
    Nagano K, Fukuda Y, Nakano I, et al. A case of the development of two hepatocellular carcinoma and a cholangiocarcinoma with cirrhosis after elimination of serum hepatitis C virus RNA with interferon therapy. Hepatogastroenterology. 2000; 47: 14361438.
  • 23
    Sugo H, Kitayama N, Iwata T, et al. Development of hepatocellular carcinoma in a patients with chronic hepatitis C after a complete response to interferon therapy. Acta Hepatol Jpn. 2000; 41: 195198.
  • 24
    Sugiura N, Sakai Y, Ebara M, et al. Detection of hepatocellular carcinoma after interferon therapy for chronic hepatitis C: clinical study of 26 cases. J Gastroenterol Hepatol. 1996; 11: 535539.
  • 25
    Kubo S, Nishiguchi S, Tamori A, et al. Resected cases of hepatocellular carcinoma detected after interferon therapy for chronic hepatitis C. Hepatogastroenterology. 2000; 47: 11001102.
  • 26
    Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology. 1994; 19: 15131520.
  • 27
    Okuda K, Kondo Y. Primary carcinoma of the liver. In: HaubrichWS, SchaffnerF, BerkJE, editors. Bockus gastroenterology. 5th edition (3), Philadelphia: WB Sanders Company, 1995: 24682472.
  • 28
    Larghi A, Tagger A, Crosignani A, et al. Clinical significance of HCV RNA in patients with chronic hepatitis C demonstrating long-term sustained response to interferon-alpha therapy. J Med Virol. 1998; 55: 711.
  • 29
    Reichard O, Glaumann H, Fryden A, et al. Two-year biochemical, virological, and histological follow-up in patients with chronic hepatitis C responding in a sustained fashion to interferon alfa-2b treatment. Hepatology. 1995; 21: 918922.
  • 30
    Balart LA, Perrillo R, Roddenberry J, et al. Hepatitis C RNA in liver of chronic hepatitis C patients before and after interferon alfa treatment. Gastroenterology. 1993; 104: 14721477.
  • 31
    Majima Y. Growth rate of hepatocellular carcinoma by ultrasonography and its clinical significance. Acta Hepatol Jpn. 1984; 25: 754765.
  • 32
    Ebara M, Ohto M, Shinagawa T, et al. Natural history of minute hepatocellular carcinoma smaller than three centimeters complicating cirrhosis. A study in 22 patients. Gastroenterology. 1986; 90: 289298.
  • 33
    Barbara L, Benzi G, Gaiani S, et al. Natural history of small untreated hepatocellular carcinoma in cirrhosis: a multivariate analysis of prognostic factors of growth rate and patient survival. Hepatology. 1992; 16: 132137.
  • 34
    Toyoda H, Kumada T, Honda T, et al. Analysis of hepatocellular carcinoma tumor growth detected in sustained responders to interferon in patients with chronic hepatitis C. J Gastroenterol Hepatol. 2001; 16: 11311137.
  • 35
    Okanoue T, Itoh Y. Hepatocellular carcinoma in sustained responders of interferon treated chronic hepatitis C. J Gastroenterol Hepatol. 2003; 18: 121123.